GlassScriptPhysician profile
Allison S Cross
NPI 1427430917
$3,850.81
in general payments reported to CMS, 2019-2025
24 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.47 · 2022: $299 · 2023: $489 · 2024: $877 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $613.17 | 2022-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $601.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $388.65 | 2025 | |
| Ardelyx, INC. | $353.86 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $318.50 | 2024-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $190.19 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $170.76 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $152.65 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.79 | 2022-2024 | Trulance |
| Genzyme Corporation | $139.68 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $134.22 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $120.01 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $91.01 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $80.86 | 2022-2024 | Linzess |
| Aimmune Therapeutics, INC. | $75.89 | 2024-2025 | Zenpep |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $55.03 | 2023 | Stelara |
| Braintree Laboratories, INC. | $45.89 | 2022-2024 | Suflave, Sutab |
| Pfizer INC. | $37.03 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $31.47 | 2021 | |
| Novo Nordisk INC | $28.90 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $26.67 | 2022 | |
| Celltrion USA INC. | $18.78 | 2025 | Vegzelma |
| Eagle Pharmaceuticals, INC. | $15.67 | 2023 | |
| Exact Sciences Corporation | $14.14 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.